CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-NK 细胞治疗：克服肿瘤学挑战的变革性策略
英文原题：CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges.
查看英文原题
CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
将嵌合抗原受体（CAR）导入自然杀伤（NK）细胞用于癌症治疗正受到越来越多关注，标志着癌症治疗领域的重要转变。本综述探讨CAR-NK细胞疗法在癌症免疫治疗中的潜力，并提供新的视角。文章讨论CAR-NK设计和工程化的创新策略，尤其关注难治或复发性癌症。通过与传统疗法比较，综述强调CAR-NK细胞应对肿瘤异质性和免疫抑制的独特能力。此外，文章阐释新型细胞因子和受体如何增强CAR-NK细胞的疗效、特异性和功能。本综述强调，与CAR-T 细胞相比，CAR-NK具有毒性较低、成本较低及可及性更广等优势，并可能用于治疗血液系统恶性肿瘤和实体瘤。
展开英文摘要原文
The use of chimeric antigen receptor (CAR) in natural killer (NK) cells for cancer therapy is gaining momentum, marking a significant shift in cancer treatment. This review aims to explore the potential of CAR-NK cell therapy in cancer immunotherapy, providing a fresh perspective.
It discusses the innovative approaches in CAR-NK cell design and engineering, particularly targeting refractory or recurrent cancers. By comparing CAR-NK cells with traditional therapies, the review highlights their unique ability to tackle tumor heterogeneity and immune system suppression.
Additionally, it explains how novel cytokines and receptors can enhance CAR-NK cell efficacy, specificity, and functionality. This review underscores the advantages of CAR-NK cells, including reduced toxicity, lower cost, and broader accessibility compared to CAR-T cells, along with their potential in treating both blood cancers and solid tumors.
论文信息
- 作者
- Li W、Wang X、Zhang X、Aziz AUR、Wang D
- 单位
- China Key Laboratory for Early Diagnosis and Biotherapy of Malignant Tumors in Children and Women, Dalian Women and Children's Medical Group, Dalian 116012, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Biomolecules2024 Aug 20
- 原文标识
- PubMed 39199421 · DOI 10.3390/biom14081035
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →